137 related articles for article (PubMed ID: 35765957)
1. ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma.
Gu J; Xu S; Chen X; Luo H; Tan G; Qi W; Ling F; Wang C; Maimaiti F; Chen Y; Yang L; Yin M; Chen D
Bosn J Basic Med Sci; 2022 Oct; 22(6):949-958. PubMed ID: 35765957
[TBL] [Abstract][Full Text] [Related]
2. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer.
Zhu HZ; Zhou WJ; Wan YF; Ge K; Lu J; Jia CK
World J Gastroenterol; 2020 Feb; 26(8):804-817. PubMed ID: 32148378
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of SLC46A3 to oppose the progression of hepatocellular carcinoma and its effect on sorafenib therapy.
Zhao Q; Zheng B; Meng S; Xu Y; Guo J; Chen LJ; Xiao J; Zhang W; Tan ZR; Tang J; Chen L; Chen Y
Biomed Pharmacother; 2019 Jun; 114():108864. PubMed ID: 30981107
[TBL] [Abstract][Full Text] [Related]
4. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
[TBL] [Abstract][Full Text] [Related]
5. [Pan-cancer analysis of the expression pattern of long non-coding RNA MIR22HG].
Wang H; Li W; Zhang D
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Apr; 42(4):473-485. PubMed ID: 35527483
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive network analysis of the molecular mechanisms associated with sorafenib resistance in hepatocellular carcinoma.
Lin H; Zhang R; Wu W; Lei L
Cancer Genet; 2020 Jul; 245():27-34. PubMed ID: 32559715
[TBL] [Abstract][Full Text] [Related]
7. TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Tan W; Luo X; Li W; Zhong J; Cao J; Zhu S; Chen X; Zhou R; Shang C; Chen Y
EBioMedicine; 2019 Feb; 40():446-456. PubMed ID: 30594557
[TBL] [Abstract][Full Text] [Related]
8. Orosomucoid in liver diseases.
Elpek GO
World J Gastroenterol; 2021 Dec; 27(45):7739-7747. PubMed ID: 34963738
[TBL] [Abstract][Full Text] [Related]
9. The hsa_circRNA_102049 mediates the sorafenib sensitivity of hepatocellular carcinoma cells by regulating
Wang S; Liu D; Wei H; Hua Y; Shi G; Qiao J
Bioengineered; 2022 Feb; 13(2):2272-2284. PubMed ID: 35034536
[TBL] [Abstract][Full Text] [Related]
10. Long Noncoding RNA (lncRNA) Small Nucleolar RNA Host Gene 16 (SNHG16) Predicts Poor Prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Guo Z; Zhang J; Fan L; Liu J; Yu H; Li X; Sun G
Med Sci Monit; 2019 Mar; 25():2079-2086. PubMed ID: 30893293
[TBL] [Abstract][Full Text] [Related]
11. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
12. Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma.
Su WL; Chuang SC; Wang YC; Chen LA; Huang JW; Chang WT; Wang SN; Lee KT; Lin CS; Kuo KK
Cancer Biomark; 2020; 28(3):341-350. PubMed ID: 32390596
[TBL] [Abstract][Full Text] [Related]
13. Salivary orosomucoid 1 as a biomarker of hepatitis B associated hepatocellular carcinoma.
He J; Zheng Z; Liu T; Ao Y; Yang Y; Hu H
Sci Rep; 2022 Sep; 12(1):15347. PubMed ID: 36096917
[TBL] [Abstract][Full Text] [Related]
14. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
[TBL] [Abstract][Full Text] [Related]
15. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma.
Zhan Z; Guan Y; Mew K; Zeng W; Peng M; Hu P; Yang Y; Lu Y; Ren H
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G305-G312. PubMed ID: 31736338
[TBL] [Abstract][Full Text] [Related]
16. Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells.
Liao LZ; Chen CT; Li NC; Lin LC; Huang BS; Chang YH; Chow LP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33379356
[TBL] [Abstract][Full Text] [Related]
17. Dramatically changed immune-related molecules as early diagnostic biomarkers of non-small cell lung cancer.
Ye X; Zhang N; Jin Y; Xu B; Guo C; Wang X; Su Y; Yang Q; Song J; Yu W; Cheng P; Cheng L; Gong Y; Fu X; Sun H
FEBS J; 2020 Feb; 287(4):783-799. PubMed ID: 31482685
[TBL] [Abstract][Full Text] [Related]
18. Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Jiang H; Ning G; Wang Y; Lv W
Dis Markers; 2021; 2021():5576683. PubMed ID: 34221187
[TBL] [Abstract][Full Text] [Related]
19. Maternal embryonic leucine zipper kinase serves as a potential prognostic marker and leads to sorafenib chemoresistance modified by miR-142-5p in hepatocellular carcinoma.
Li H; Gai L; Wu Z; Li F
Mol Biol Rep; 2022 Apr; 49(4):3015-3024. PubMed ID: 35013864
[TBL] [Abstract][Full Text] [Related]
20. miR-3607, a biomarker of hepatocellular carcinoma invasion and aggressiveness: Its relationship with epithelial-mesenchymal transition process.
Hu WY; Wei HY; Liu LY; Li KM; Wang RB; Xu XQ; Feng R
IUBMB Life; 2020 Aug; 72(8):1686-1697. PubMed ID: 32311821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
